Premium
Polysaccharide‐Peptide Cryogels for Multidrug‐Resistant‐Bacteria Infected Wound Healing and Hemostasis
Author(s) -
Hou Sen,
Liu Yuanyuan,
Feng Fang,
Zhou Jin,
Feng Xinxing,
Fan Yubo
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201901041
Subject(s) - antimicrobial , bacteria , hemostasis , wound healing , hemostatic agent , microbiology and biotechnology , multiple drug resistance , antimicrobial peptides , wound care , medicine , antibiotics , biology , immunology , surgery , genetics
Wound dressings that can simultaneously treat bacterial infections and various bleeding complications are highly desirable in clinics. Moreover, multidrug‐resistant (MDR) bacterial infection has posed another great challenge for clinical wound care, as there are fewer effective antimicrobial agents available for killing these bacteria. To meet the clinical need, serials of polysaccharide‐peptide cryogels have been developed with excellent antibacterial efficacy and hemostatic property. With glycol chitosan (GC) and ε‐poly lysine (EPL) as the major components, the cryogels yield significantly lower amounts of blood loss compared with commercially available hemostatic dressings. The incorporation of EPL significantly enhances the antibacterial activity including killing MDR bacteria capacity and prevents the bacterial infection of skin wounds. The cryogel treated wounds demonstrate significantly higher healing efficiency compared to the controlled MDR bacteria infected wounds. The GC‐EPL polysaccharide‐peptide cryogels may become competitive multifunctional wound dressings for bleeding control and bacteria‐infected wound healing.